Myo-Inositol Trispyrophosphate (ITPP) Sodium – Powder, 1g

$1.00

Myo-Inositol Trispyrophosphate (ITPP) Sodium – Powder, 1g is ultra-pure, analytical-grade inositol pyrophosphate compound with ≥98% purity, designed for in vitro/in vivo metabolic research and analytical testing. This lyophilized material functions as a pyrophosphate derivative of phytic acid and a powerful, allosteric effector of hemoglobin that crosses the plasma membrane of red blood cells, lowering the affinity of hemoglobin for oxygen and shifting the oxygen-hemoglobin dissociation curve to the right, thereby increasing oxygen release from blood into tissue and improving tissue oxygenation, making it invaluable for investigators studying endurance enhancement, cardiovascular disease, cancer treatment adjuvant therapy, tissue hypoxia reduction, exercise performance, hypoxia reversal, tumor growth control, chemotherapy response improvement, and oxygen delivery mechanisms. Rodent studies demonstrated increased tissue oxygenation and dose-dependent increases in endurance during physical exercise in both healthy mice and transgenic mice expressing a heart failure phenotype. Available for fast, compliant shipping to all U.S. states and European countries via dedicated logistics hubs.

  • Third-party certified lot coding with publicly available COA (Certificate of Analysis) for absolute purity transparency

  • Formulation completely free of adulterants, excipients, flow agents, and other compounds to guarantee raw chemical purity

  • Precision over-weighed by 5-10% inside vessel to compensate for natural adhesion loss during laboratory powder transfer

  • UV-resistant PET single-wall jar with tamper-proof seal engineered for transit safety and chemical stability

Category:
Description

Myo-Inositol Trispyrophosphate (ITPP) Sodium – Powder, 1g

This premium, laboratory-grade research compound delivers ultra-pure raw ITPP Sodium powder at ≥98% purity, representing the highest standard for modern scientific investigations into hemoglobin allosteric regulation and tissue oxygenation enhancement mechanisms. The lyophilized crystalline powder form provides investigators with a single-compound reference standard ideal for analytical testing, in vitro blood sample modeling of hemoglobin-oxygen interactions, and in vivo preclinical research applications where precise ITPP administration is critical for studying endurance enhancement, cardiovascular disease, and cancer treatment adjuvant therapy.

All shipments to the 50 United States are fulfilled directly from primary U.S. production facilities, ensuring 2-5 business day delivery nationwide. International orders to the United Kingdom and continental Europe are processed through our dedicated United Kingdom shipping hub, which streamlines customs clearance and reduces transit times across all European countries. This dual-hub logistics infrastructure guarantees seamless, compliant delivery while maintaining chemical integrity throughout transit.

  • Public third-party lab reports with unique lot-coding ensure absolute transparency for every batch sold

  • Formulation contains zero adulterants, excipients, flow agents, or contaminants—pure ITPP Sodium only

  • Strategic over-weighing compensates for powder adhesion loss, guaranteeing minimum 1g recoverable material

  • PET single-wall jar features UV-resistant construction and tamper-proof seal for transit safety


Technical Specifications & Chemical Profile

Chemical Property Specification Data
Product Name Myo-Inositol Trispyrophosphate (ITPP) Sodium – Powder, 1g
Common Synonyms ITPP Sodium, ITPP, Inositol Pyrophosphate, Pyro-Ins-Na, myo-Inositol 1,6:2,3:4,5 trispyrophosphate sodium salt, myo-Inositol cyclic 1,2:3,4:5,6-tris(P,P’-dihydrogen diphosphate), Phytic Acid Pyrophosphate Derivative, OXY111A
CAS Number 623552-11-4 / 802590-64-3 / 23103-35-7 (hexasodium salt)
Molecular Formula C₆H₈Na₄O₂₁P₆ (tetrasodium); C₆H₆Na₆O₂₁P₆ (hexasodium)
Molar Mass 693.91 g/mol (tetrasodium); 737.88 g/mol (hexasodium)
Primary Target Mechanism Inositol phosphate; pyrophosphate; pyrophosphate derivative of phytic acid; drug candidate; putative performance-enhancing substance; powerful allosteric effector of hemoglobin; membrane-permeant allosteric regulator of hemoglobin; crosses plasma membrane of red blood cells; reduces hemoglobin oxygen-binding affinity; shifts oxygen-hemoglobin dissociation curve to the right; increases oxygen release from blood into tissue; increases tissue oxygenation; increases endurance during physical exercise (dose-dependent); improves cardiovascular function; reduces tissue hypoxia; anti-cancer properties; reverses hypoxia; controls tumor growth; improves chemotherapy response; adjuvant use with chemotherapy; cardiovascular disease research; cancer study; healthy mice endurance enhancement; transgenic mice with heart failure phenotype; high potential for athletic doping; detectable in urine via liquid chromatography-mass spectrometry; suspected use in horse racing doping; human clinical trials registered 2014 (OXY111A); enhances oxygen release capacity of red blood cells
Physical Form White crystalline powder (lyophilized)

Research Applications & Storage Protocols

Hemoglobin Allosteric Regulation & Tissue Oxygenation Profiling

myo-Inositol trispyrophosphate (ITPP) functions as an inositol phosphate, a pyrophosphate, a drug candidate, and a putative performance-enhancing substance, which exerts its biological effects by increasing tissue oxygenation. The compound is a pyrophosphate derivative of phytic acid with the molecular formula C₆H₁₂O₂₁P₆ (free acid form). ITPP is a membrane-permeant allosteric regulator of hemoglobin that mildly reduces its oxygen-binding affinity, which shifts the oxygen-hemoglobin dissociation curve to the right and thereby increases oxygen release from the blood into tissue. This compound was found to be a powerful, allosteric effector of hemoglobin and is also able to cross the plasma membrane of the red blood cells in whole blood samples, lowering the affinity of hemoglobin for oxygen. Rodent studies in vivo demonstrated increased tissue oxygenation and dose-dependent increases in endurance during physical exercise, in both healthy mice and transgenic mice expressing a heart failure phenotype, confirming its efficacy for endurance enhancement. The substance is believed to have a high potential for use in athletic doping, and liquid chromatography–mass spectrometry tests have been developed to detect ITPP in urine tests. Its use as a performance-enhancing substance in horse racing has also been suspected and similar tests have been developed for horses. ITPP has been studied for potential adjuvant use in the treatment of cancer in conjunction with chemotherapy, due to its effects in reducing tissue hypoxia, demonstrating therapeutic potential beyond endurance enhancement. myo-Inositol trispyrophosphate (ITPP) hexasodium salt is a drug with anti-cancer properties and is an allosteric effector that interacts with hemoglobin, further supporting its role in cancer research. myo-Inositol trispyrophosphate (ITPP) hexasodium can be used in the study of cardiovascular disease and cancer, expanding its research applications. myo-Inositol trispyrophosphate (ITPP) hexasodium enhances the oxygen release capacity of red blood cells by reducing the affinity of hemoglobin to oxygen, confirming its mechanism of action. myo-Inositol trispyrophosphate (ITPP) hexasodium, a modifier of haemoglobin, is an allosteric effector that reduces the oxygen‐binding affinity of haemoglobin and facilitates the release of oxygen by red blood cells. myo-Inositol trispyrophosphate can reverse hypoxia, control tumor growth and improve chemotherapy response, demonstrating comprehensive therapeutic potential. Myo-inositol Trispyrophosphate (ITPP) is an inositol phosphate, a pyrophosphate, a drug candidate, and a putative performance-enhancing substance, confirming its multifaceted research applications. This hemoglobin allosteric regulation mechanism positions ITPP as a critical tool compound for investigating endurance enhancement research, cardiovascular disease models, cancer treatment adjuvant therapy studies, tissue hypoxia reduction pathways, exercise performance mechanisms, hypoxia reversal, tumor growth control, chemotherapy response improvement, and oxygen delivery mechanisms in preclinical models, offering potential therapeutic insights for multiple disease states.

Handling & Storage Guidelines

  • Long-Term Storage: Store at room temperature or below in a cool, dry place; keep cool and dry; protect from moisture; stable when stored properly; avoid excessive heat and humidity

  • Solubility: Soluble in water; prepare fresh solutions immediately before use; aqueous solutions are stable for short-term storage at 2-8°C (39°F); avoid prolonged storage of solutions

  • Appearance: White powder; clear colorless solutions in water when properly dissolved

Global Logistics & Order Fulfillment

We proudly support scientific advancement across all 50 U.S. states and throughout Europe. Customers can seamlessly toggle their preferred currency between USD and EUR using the currency switcher located on the left-hand side of our website. All shipments are securely packaged to withstand international transit without compromising structural or chemical stability.

Laboratory Use Only Disclaimer

This material is sold strictly for laboratory research and development use only. It is not approved for human consumption, nor for medical, veterinary, or household applications. All purchases are governed by our standard Terms & Conditions. Please review them carefully before placing your order.

Additional information
pa_feature

Discountinued

pa_form

Powders

pa_types

SARMs

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Myo-Inositol Trispyrophosphate (ITPP) Sodium – Powder, 1g”